Large-cell neuroendocrine carcinoma of the lung: A focused analysis of BRAF alterations and case report of a BRAF non-V600- mutated tumor responding to targeted therapy

Young Kwang Chae*, Keerthi B. Tamragouri, Jon Chung, Xiaoqi Lin, Vincent Miller, Siraj M. Ali, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Purpose In advanced stages, large-cell neuroendocrine carcinoma of the lung (L-LCNEC) mimics small-cell lung cancer despite its traditional classification as a non- small-cell lung cancer. Here we present a focused analysis of BRAF mutations in this population. Patients and Methods Comprehensive genomic profiling of tumor tissues was performed from a cohort of 300 patients with biopsy-proven L-LCNEC. Specimens were either from a primary lung lesion or metastatic site. Results In 13 patients, 14 unique BRAF alterations (amplifications, mutations) were identified. The importance of biomarker-driven therapy is subsequently highlighted with our case of a 69-year-old man diagnosed with metastatic L-LCNEC who did not respond to cisplatin plus etoposide. A significant durable response was then demonstrated with therapy targeted toward a BRAF non-V600E activating mutation (G469R) associated with biomarker response identified through circulating cell-free tumor DNA analysis. A change in clonal allele frequency from nearly 40% to nondetectable was observed. Conclusion Although uncommon, L-LCNEC does seem to contain activating and therefore actionable alterations. We thus highlight the value of pursuing next-generation sequencing for patients with this disease.

Original languageEnglish (US)
JournalJCO Precision Oncology
Volume2
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Large-cell neuroendocrine carcinoma of the lung: A focused analysis of BRAF alterations and case report of a BRAF non-V600- mutated tumor responding to targeted therapy'. Together they form a unique fingerprint.

Cite this